LILRA4 and systemic lupus erythematosus: Targeting ILT7 with the monoclonal antibody VIB7734 significantly reduced circulating and skin-resident pDCs in patients with cutaneous lupus erythematosus, leading to decreased local IFN-I activity and clinical improvement [165,166], while transient pDC depletion in a lupus-prone mouse model similarly diminished immune cell activation, autoantibody production, and kidney inflammation, underscoring the central role of pDC-driven IFN-I in lupus pathogenesis [167].